Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs NetEase Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while NetEase Inc trades at $124.61 (market cap $80.44B). The key difference: NetEase Inc is far larger — about 9.1× Kymera Therapeutics Inc. Common Stock's market cap, and NetEase Inc pays a 2.37% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and NetEase Inc for 73 Days on average.
| KYMR | NTES | |
|---|---|---|
Market Cap | $8.88B | $80.44B |
Volume | 1,028,790 | 626,220 |
Sector | Health | Technology |
52-Week High | $127.31 | $152.85 |
52-Week Low | $55.80 | $109.26 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $8.27B | $56.12B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NTES trades at $124.76, down 0.52% on the day, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 revenue growth of 8% year-over-year to $4.4 billion, though EPS missed expectations. Fundamentals remain strong with a 27.88% net income margin and robust cash flow from operations of $50.74 billion in 2025. Analyst sentiment is overwhelmingly positive with an 81.82% buy rating and a consensus price target of $168.00, suggesting significant upside potential from current levels.
The outlook for NTES is favorable, supported by solid profitability, a strong balance sheet with $137.58 billion in cash, and strategic investments in AI and global expansion. Key risks include earnings volatility, as seen in recent misses, and competitive pressures in the gaming sector. The stock presents a compelling opportunity for growth investors, with technical indicators aligning with fundamental strength, though monitoring quarterly execution remains critical for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
